JPH10127763A - Selective transmitting hollow string film - Google Patents
Selective transmitting hollow string filmInfo
- Publication number
- JPH10127763A JPH10127763A JP28825596A JP28825596A JPH10127763A JP H10127763 A JPH10127763 A JP H10127763A JP 28825596 A JP28825596 A JP 28825596A JP 28825596 A JP28825596 A JP 28825596A JP H10127763 A JPH10127763 A JP H10127763A
- Authority
- JP
- Japan
- Prior art keywords
- hollow fiber
- molecular weight
- fiber membrane
- dextran
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は選択透過性中空糸膜
に関するものである。更に詳しくは、水溶液系でのデキ
ストランの篩係数に対する、牛血漿系でのアルブミンの
篩係数の比が特定の値以下であり、血漿系での優れた分
離性能を呈する選択透過性を有するもので、血液透析、
血液濾過透析等の血液処理に適し、特に中高分子量領域
の有害物質を除去するのに適した選択透過性中空糸膜を
提供するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a selectively permeable hollow fiber membrane. More specifically, the ratio of the sieving coefficient of albumin in the bovine plasma system to the sieving coefficient of dextran in the aqueous solution system is equal to or less than a specific value, and has a selective permeability exhibiting excellent separation performance in the plasma system. , Hemodialysis,
It is an object of the present invention to provide a selectively permeable hollow fiber membrane suitable for blood treatment such as hemofiltration dialysis, and particularly suitable for removing harmful substances in a medium-high molecular weight region.
【0002】[0002]
【従来の技術】選択透過性中空糸膜は、逆浸透や血液透
析等において従来より実用的に使用されてきている。特
に腎不全患者の血液を浄化するために、現在では中空糸
型血液透析器がよく使用されている。これは筐体の中に
透析膜、例えば、中空糸の膜を多数本収納し、その中空
内部に患者の血液を流し、外部、すなわち、中空糸間隙
部に透析液を流して、中空糸膜壁を介して透析によっ
て、血液中の老廃物を除去し電解質濃度を是正するとと
もに、中空糸内外に圧力差を与えて限外濾過によって血
液中の余剰水分を除去するものである。更に、血液中か
ら血漿のみを分離し、あるいは、その血漿の中から特定
成分を除去して自己免疫疾患などを治療するために、中
空糸が使用されることもある。また最近になってタンパ
ク透過性血液透析やタンパク透過性血液濾過透析に中空
糸を用いることによって治療効果が得られることが確認
されるようになってきている。2. Description of the Related Art Permselective hollow fiber membranes have been practically used in reverse osmosis and hemodialysis. In particular, hollow fiber hemodialyzers are often used at present for purifying blood of patients with renal failure. This is a method in which a dialysis membrane, for example, a number of hollow fiber membranes, is housed in a housing, a patient's blood flows inside the hollow, and a dialysate flows through the outside, that is, a hollow fiber gap, and a hollow fiber membrane is formed. In addition to removing wastes in the blood and correcting the electrolyte concentration by dialysis through the wall, a pressure difference is applied between the inside and outside of the hollow fiber to remove excess water in the blood by ultrafiltration. Furthermore, hollow fibers are sometimes used to separate plasma alone from blood or to remove specific components from the plasma to treat autoimmune diseases and the like. Recently, it has been confirmed that a therapeutic effect can be obtained by using hollow fibers in protein-permeable hemodialysis or protein-permeable hemofiltration dialysis.
【0003】このように血液処理用の中空糸は目的に応
じて特定の物質を選択的に透過せしめなければならな
い。その性能は、中空糸の素材、ポロシテイ(孔の大き
さ、数など)、膜厚等によって決定される。As described above, a hollow fiber for blood treatment must selectively allow a specific substance to permeate according to the purpose. The performance is determined by the material of the hollow fiber, the porosity (the size and number of holes), the film thickness and the like.
【0004】ところで、近年、透析患者の長期合併症と
関連し、透析アミロイドシスの原因物質と考えられるβ
2 ―MG(ミクログロブリン)(分子量11,800)
掻痒感、高脂血症と関係すると考えられる副甲状腺ホル
モン(分子量約9,500)、貧血に関与する赤芽球抑
制因子、関節痛、骨痛に係わると考えられる分子量2〜
4万の物質、など比較的中高分子量領域の有害物質の除
去の必要性がさけばれている。一方、人体に必須のアル
ブミン(分子量66,000)の損失は極力避けなけれ
ばならない。すなわち、分子量4〜5万以下の物質の透
過性に優れ、一方分子量6万以上の物質の阻止性のよい
分画分子量のシャープカット性の良好な選択透過性膜が
望まれている。[0004] In recent years, β which is considered to be a causative substance of dialysis amyloidosis is associated with long-term complications of dialysis patients.
2- MG (microglobulin) (molecular weight 11,800)
Parathyroid hormone (molecular weight about 9,500), which is thought to be associated with pruritus and hyperlipidemia, erythroblast inhibitory factor involved in anemia, molecular weight 2 which is thought to be involved in arthralgia and bone pain
The need to remove harmful substances in the relatively high molecular weight region, such as 40,000 substances, is avoided. On the other hand, loss of albumin (molecular weight: 66,000), which is essential for the human body, must be avoided as much as possible. That is, there is a demand for a permselective membrane which is excellent in permeability of substances having a molecular weight of 40,000 or less and 50,000 or less, and which has good rejection of substances having a molecular weight of 60,000 or more and a good sharp cut property of a cut molecular weight.
【0005】しかるに、従来、ポリサルホンなどの合成
高分子では、例えば特公平2―18695号や特公平5
―54373号にみられるように、比較的上記要求を満
たしたものが得られているが、セルロース誘導体特にト
リアセテートでは、例えば特公昭58―34165号に
みられるように、中空糸を湿式紡糸するときの芯剤に、
流動パラフィン、高級アルコール、イソプロピルミリス
テートなど、トリアセテート紡糸原液に対し凝固性のな
いものを使用するために、紡糸原液におけるトリアセテ
ートの濃度を高め、紡糸時の曵糸性を高くせざるを得な
い。また、紡糸原液をノズルから出糸後、中空糸外面か
ら凝固液で固化させるために、中空糸外面に緻密構造の
層が形成される。However, conventionally, synthetic polymers such as polysulfone are disclosed in, for example, Japanese Patent Publication No.
As described in JP-A-54373, those which relatively satisfy the above requirements have been obtained. However, in the case of cellulose derivatives, particularly triacetate, for example, as shown in JP-B-58-34165, when hollow fibers are wet-spun. For the core agent,
In order to use non-coagulable triacetate spinning solution such as liquid paraffin, higher alcohol, and isopropyl myristate, it is necessary to increase the concentration of triacetate in the spinning solution to increase spinnability during spinning. In addition, a layer having a dense structure is formed on the outer surface of the hollow fiber in order to solidify the spinning stock solution from the nozzle and then solidify the outer surface of the hollow fiber with the coagulating liquid.
【0006】これらの理由により、従来、セルロース誘
導体中空糸は、合成ポリマーの膜に比し、構造の緻密層
と多孔層の密度差が小さく、全体として均一層に近く、
物質の透過性能が十分とはいえなかった。そのために膜
の厚さを減少せしめ、透過性の向上を図ってきたが、十
分なものとはいえない。更に、膜構造の緻密層と多孔層
の密度差が不明確なために、透過物質の分画特性におい
ても、改良の余地のあるものであった。[0006] For these reasons, conventionally, a cellulose derivative hollow fiber has a smaller difference in density between a dense layer and a porous layer in structure than a synthetic polymer membrane, and is close to a uniform layer as a whole.
The permeability of the substance was not sufficient. For this purpose, the thickness of the film has been reduced and the permeability has been improved, but this is not sufficient. Furthermore, since the density difference between the dense layer and the porous layer having a membrane structure is unclear, there is room for improvement in the fractionation characteristics of the permeated substance.
【0007】[0007]
【発明が解決すべき課題】本発明は、このような従来技
術の問題点を解決することを目的とするものであって、
セルロース誘導体のポリマーを使用して従来の合成ポリ
マーの構造に近い粗密構造を与え、高い分子量分画特性
を付与することである。特に血液透析や血液濾過透析に
おいてβ2 ―MG等の中高分子量領域の有害物質の除去
とアルブミンなどの有用物質の流出阻止を高めることが
可能な選択透過性中空糸膜を提供することを目的として
いる。SUMMARY OF THE INVENTION An object of the present invention is to solve such problems of the prior art.
The purpose of the present invention is to provide a close-packed structure close to the structure of a conventional synthetic polymer by using a polymer of a cellulose derivative, and to impart high molecular weight fractionation characteristics. In particular, it is an object of the present invention to provide a selectively permeable hollow fiber membrane capable of removing harmful substances in the medium-high molecular weight region such as β 2 -MG and preventing outflow of useful substances such as albumin in hemodialysis and hemodiafiltration. I have.
【0008】[0008]
【課題を解決するための手段】本発明者は、かかる目的
を達成するために鋭意努力した結果、水溶液系でのデキ
ストランの篩係数に対する、牛血漿系でのアルブミンの
篩係数の比が、特定の値以下である中空糸を用いた血液
透析器が、飛躍的に高められた中高分子量物質の分離性
能を発揮することを見い出し、本発明に到達した。Means for Solving the Problems As a result of the inventor's intensive efforts to achieve such an object, the ratio of the sieving coefficient of albumin in the bovine plasma system to the sieving coefficient of dextran in the aqueous solution system was determined. It has been found that a hemodialyzer using a hollow fiber having a value equal to or less than the value exhibits a remarkably enhanced separation performance of a medium-high molecular weight substance, and has reached the present invention.
【0009】すなわち、本発明は、選択透過性を有する
中空糸膜であり、該中空糸膜を透析器として組立て測定
した、分子量70,000のデキストランの水溶液を使
用した該デキストランの篩係数(SCDX)が0.05以
上であり、かつSCDXに対する、牛血漿を1時間灌流し
た後のアルブミンの篩係数(SCAI b )の比SCAI b/
SCDXが0.12未満であることを特徴とする、実質的
にセルロース誘導体からなる選択透過性中空糸膜であ
る。That is, the present invention relates to a hollow fiber membrane having permselectivity, and a sieving coefficient (SC) of the dextran using an aqueous solution of dextran having a molecular weight of 70,000, which was measured by assembling the hollow fiber membrane as a dialyzer. DX) is not less than 0.05, and for SC DX, the ratio of the sieving coefficient of albumin after 1 hour perfused bovine plasma (SC AI b) SC AI b /
A permselective hollow fiber membrane consisting essentially of a cellulose derivative, having an SC DX of less than 0.12.
【0010】以下、本発明について更に詳細に説明す
る。Hereinafter, the present invention will be described in more detail.
【0011】すなわち、本発明における中空糸膜は、選
択透過性を有するものであり、その素材としては、セル
ロース誘導体、特にアセチルセルロースであり、その中
でも一般的に使用されるものとしては、実質的にセルロ
ースジアセテート、セルローストリアセテートからなる
高分子である。なお、実質的とは、このセルロース誘導
体の特性を損わない範囲で、他の高分子、添加物などを
含有してもよいことを意味する。That is, the hollow fiber membrane of the present invention has a selective permeability, and is made of a cellulose derivative, particularly acetylcellulose. And a polymer composed of cellulose diacetate and cellulose triacetate. Note that “substantially” means that other polymers, additives, and the like may be contained as long as the properties of the cellulose derivative are not impaired.
【0012】また本発明の中空糸膜の膜壁の構造に関し
ては、物質の分離透過特性と機械特性を機能分担させる
ような、極薄緻密層と、機械的に流体圧力に耐えられる
が、物質の透過抵抗には殆んどならない多孔層とを合せ
持つような、従来、合成高分子で実現されていた2層又
は多層構造が好ましい。特に、中空糸膜の内面を通して
血液を処理する場合には、少くとも中空糸内面に緻密層
があるのが望ましい。内面に多孔層があると、その部分
に血中蛋白が付着したり、あるいは孔中に侵入したりし
て、物質透過の阻害になる懸念がある。The structure of the membrane wall of the hollow fiber membrane of the present invention is characterized by an ultra-thin dense layer that functions to separate and permeate the separation and permeation characteristics of the substance and the mechanical properties, and is capable of mechanically withstanding fluid pressure. A two-layer or multi-layer structure conventionally realized by a synthetic polymer, which has a porous layer having almost no permeation resistance, is preferable. In particular, when blood is processed through the inner surface of the hollow fiber membrane, it is desirable that there is a dense layer at least on the inner surface of the hollow fiber. If there is a porous layer on the inner surface, there is a concern that blood proteins may adhere to that portion or penetrate into the pores, thereby impeding the permeation of substances.
【0013】例えば、この様に、中空糸内面に薄い緻密
層を有し、その外側に多孔層を有する膜においては、水
溶液系の中大分子、例えばデキストラン(分子量70,
000)の物質は、比較的大きい篩係数を示すが、血漿
又は全血系での同様の分子量のアルブミンの篩係数は小
さくなる事を見い出した。この場合中大分子量物質の濾
過による篩係数は、血漿系では水系に比べて大幅に低下
するのに対し、拡散による透過係数は殆ど影響ないこと
も判明した。For example, as described above, in a membrane having a thin dense layer on the inner surface of a hollow fiber and a porous layer on the outer side, a medium- or large-molecule aqueous solution such as dextran (molecular weight 70,
000) shows a relatively high sieving coefficient, but the sieving coefficient of albumin of similar molecular weight in plasma or whole blood system is found to be lower. In this case, it was also found that the sieving coefficient by filtration of the medium and large molecular weight substances was significantly lower in the plasma system than in the aqueous system, while the permeability coefficient by diffusion had little effect.
【0014】この様に、水溶液等に対する血漿系の中大
分子の篩係数の低下率がある一定値以下の値を示す様な
構造を有する中空糸膜においては、その中大分子の拡散
による透過(透析性能)を低下させることなく、濾過に
よる透過を減少させることができ、例えば、分子量1
0,000程度の物質と分子量70,000程度の物質
の分離特性を大幅に向上させることができる。As described above, in a hollow fiber membrane having a structure in which the reduction rate of the sieving coefficient of a medium-large molecule in a plasma system to an aqueous solution or the like shows a certain value or less, the permeation of the medium-large molecule by diffusion (Dialysis performance) can be reduced without lowering the permeation by filtration.
The separation characteristics of a substance having a molecular weight of about 7000 and a substance having a molecular weight of about 70,000 can be greatly improved.
【0015】セルロース誘導体系の中空糸膜におけるこ
の様な傾向は、今回はじめて実証された。This tendency of the cellulose derivative-based hollow fiber membrane has been demonstrated for the first time.
【0016】また従来のトリアセテート、ジアセテート
の様なセルロース誘導体の透析用の中空糸膜は、一般に
均一膜であり、水溶液系に対する血漿系の中大分子の篩
係数の比は0.12以上を示した。A conventional hollow fiber membrane for dialysis of a cellulose derivative such as triacetate or diacetate is generally a uniform membrane, and the ratio of the sieving coefficient of the medium and large molecules of the plasma to the aqueous solution is 0.12 or more. Indicated.
【0017】なお、ここで篩係数の測定は、日本透析医
学会学術委員会の「血液浄化器」評価基準に基づいて測
定した。The sieving coefficient was measured based on the "Blood Purifier" evaluation standard of the Scientific Committee of the Japanese Society for Dialysis Therapy.
【0018】本発明に係わる中空糸膜は、その中空糸束
を用いて組み立てた透析器において、分子量70,00
0のデキストランの水溶液を使用した該デキストランの
篩係数SCDX)が0.05以上であり、かつSCDXに対
する、牛血漿を1時間灌流した後のアルブミンの篩係数
(SCAI b )の比SCAI b /SCDXが0.12未満であ
ることを特徴としている。好ましくは0.10以下であ
り、かかる中空糸膜は、水、低分子物質及び分子量1
0,000のデキストランの物質透過性が良好であり、
かつ、分子量が約66,000のアルブミンの中空糸膜
を通じての透過性は十分に阻止されているものであり、
これらの分子量の間にシャープな分画特性を有してい
る。The hollow fiber membrane according to the present invention has a molecular weight of 70,00 in a dialyzer assembled using the hollow fiber bundle.
The dextran sieving coefficient SC DX using an aqueous solution of dextran of 0 or more is 0.05 or more, and the ratio SC SC of the sieving coefficient of albumin (SC AI b ) after perfusion of bovine plasma for 1 hour to SC DX AI b / SC DX is characterized in that less than 0.12. Preferably, it is 0.10 or less, and such a hollow fiber membrane is composed of water, a low molecular weight substance and a molecular weight of 1
The material permeability of dextran of 000 is good,
In addition, the permeability of albumin having a molecular weight of about 66,000 through the hollow fiber membrane is sufficiently prevented,
It has sharp fractionation characteristics between these molecular weights.
【0019】中空糸膜の膜厚は、一般に物質の透過性か
らみれば薄いのが望ましいが、本発明に係わるような2
層以上の構造のものでは、多孔層を有するために機械的
強度の点より30μm以上が好ましい。なお、中空糸膜
の内径は100〜300μm、更には150〜250μ
mが好ましい。The thickness of the hollow fiber membrane is generally desirably small in view of the permeability of the substance.
In the case of a structure having two or more layers, the thickness is preferably 30 μm or more from the viewpoint of mechanical strength because of having a porous layer. The inner diameter of the hollow fiber membrane is 100 to 300 μm, and more preferably 150 to 250 μm.
m is preferred.
【0020】また、本発明において、牛血漿系で測定し
たβ2 ―マイクログロブリンの総括物質移動係数K0 が
5.0×10-5cm/sec以上であることがあげられ
る。なお、かかるK0 の測定方法としては、β2 ―マイ
クログロブリンのクリアランス(CL)を日本透析医学
界学術委員会の評価法(1994)より測定し、次式を
用いて算出する。Further, in the present invention, the total mass transfer coefficient K 0 of β 2 -microglobulin measured in bovine plasma system is 5.0 × 10 −5 cm / sec or more. As a method of measuring K 0 , the clearance (CL) of β 2 -microglobulin is measured by the evaluation method of the Japanese Society for Dialysis Medical Academic Committee (1994), and calculated using the following equation.
【0021】[0021]
【数1】 (Equation 1)
【0022】 QB :血液側の流量[ml/sec] QD :透析液側の流量[ml/sec] A :中空糸膜有効膜面積[cm2 ]:中空糸膜の湿潤
状態での内径基準の膜面積である。Q B : flow rate on blood side [ml / sec] Q D : flow rate on dialysate side [ml / sec] A: effective membrane area of hollow fiber membrane [cm 2 ]: inner diameter of hollow fiber membrane in wet state This is the reference film area.
【0023】本発明の中空糸膜のK0 としては5.0×
10-5cm/sec以上、更に好ましくは6.0×10
-5cm/sec以上である。The K 0 of the hollow fiber membrane of the present invention is 5.0 ×
10 -5 cm / sec or more, more preferably 6.0 × 10
-5 cm / sec or more.
【0024】このように本発明の中空糸膜は、血液透析
器や血液濾過透析に使用した場合に、β2 ―MGなどの
中高分子量の領域の有害物質の除去性能が高く、かつ低
分子量領域の有害物質の除去性能も優れている上に、人
体に有益なアルブミンの損失量が少ないという選択透過
性に優れたものである。As described above, when the hollow fiber membrane of the present invention is used in a hemodialyzer or hemofiltration dialysis, it has a high ability to remove harmful substances in a medium-high molecular weight region such as β 2 -MG and has a low molecular weight region. In addition to the excellent performance of removing harmful substances, the selective permeation of albumin, which is beneficial to the human body, is small.
【0025】かかる本発明の中空糸膜の製造方法は特に
限定されるものではないが、望ましくはセルロース誘導
体を有機溶剤に溶解した紡糸原液を、芯剤として水溶液
を用いて、チューブインオリフィス状ノズルより吐出さ
せ、気体中を通過後、水溶性凝固液中に通し固化させる
方式が採用される。Although the method for producing the hollow fiber membrane of the present invention is not particularly limited, a tube-in-orifice nozzle is desirably prepared by using a spinning stock solution obtained by dissolving a cellulose derivative in an organic solvent and using an aqueous solution as a core agent. A method is adopted in which the liquid is discharged more, passes through a gas, and then passes through a water-soluble coagulating liquid and solidifies.
【0026】[0026]
【実施例】以下、本発明について、実施例をあげて更に
具体的に説明するが、本発明はこれらの実施例によって
何ら限定されるものではない。EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.
【0027】[実施例1〜6、比較例1〜5]セルロー
ストリアセテートとトリエチレングリコールを、ジメチ
ルスルホキシド(DMSO)に均一溶解したもの(トリ
エチレングリコール/DMSO=2/7(wt/w
t))を紡糸原液として、チューブインオリフィス型ノ
ズルより、各種流体を芯剤として、空気中に吐出させた
後、凝固液の中に導いて固化させ、水洗、グリセリン付
着処理後、捲取った。得られた中空糸膜を乾燥後束状に
して、円管状の容器内に挿入充填して、両端をポリウレ
タンで接着固定し、有効面積が約1.5m2 の血液透析
器を作製した。[Examples 1 to 6, Comparative Examples 1 to 5] Cellulose triacetate and triethylene glycol were uniformly dissolved in dimethyl sulfoxide (DMSO) (triethylene glycol / DMSO = 2/7 (wt / w)
Using t)) as a spinning dope, various fluids were discharged into the air from a tube-in-orifice type nozzle as a core agent, and then guided into a coagulating liquid to be solidified, washed with water, glycerin-adhering treatment, and then wound up. . The obtained hollow fiber membranes were dried and formed into a bundle, inserted and filled in a cylindrical container, and both ends were adhered and fixed with polyurethane to prepare a hemodialyzer having an effective area of about 1.5 m 2 .
【0028】表1は紡糸の条件とin vitroの特
性値及び透析性能を示したものである。本発明の中空糸
は、血漿系でのアルブミンの篩係数が小さく、β2 ―マ
イクログロブリンの透析性能が大きくなっている。Table 1 shows the spinning conditions, in vitro characteristic values and dialysis performance. The hollow fiber of the present invention has a small sieving coefficient of albumin in a plasma system and a large dialysis performance of β 2 -microglobulin.
【0029】本発明の中空糸膜は、その集束体を用いて
血液浄化器を組み立てた場合、β2―MG等の中高分子
量領域の有害物質の除去率が高いのみならず、アルブミ
ンの透析液中への漏出量が少ないという優れた効果を奏
するものである。When the hollow fiber membrane of the present invention is used to assemble a blood purifier using the bundle, not only the removal rate of harmful substances in the medium-high molecular weight region such as β 2 -MG is high but also the dialysate of albumin It has an excellent effect that the amount of leakage into the inside is small.
【0030】[0030]
【表1】 [Table 1]
Claims (4)
該中空糸膜を透析器として組立て測定した、分子量7
0,000のデキストランの水溶液を使用した該デキス
トランの篩係数(SCDX)が0.05以上であり、かつ
SCDXに対する、牛血漿を1時間灌流した後のアルブミ
ンの篩係数(SCAI b )の比SCAI b /SCDXが0.1
2未満であることを特徴とする、実質的にセルロース誘
導体からなる選択透過性中空糸膜。1. A hollow fiber membrane having permselectivity,
The hollow fiber membrane was assembled and measured as a dialyzer, and had a molecular weight of 7
The dextran sieving coefficient (SC DX ) using an aqueous solution of dextran of 000 is 0.05 or more, and the sieving coefficient of albumin after perfusing bovine plasma with SC DX for 1 hour (SC AI b ) The ratio SC AI b / SC DX is 0.1
A permselective hollow fiber membrane substantially consisting of a cellulose derivative, wherein the number is less than 2.
に緻密層を有する特許請求の範囲第1項に記載の選択透
過性中空糸膜。2. The permselective hollow fiber membrane according to claim 1, wherein the permselective hollow fiber membrane has a dense layer at least on an inner surface.
以上である特許請求の範囲第1項に記載の選択透過性中
空糸膜。3. The selectively permeable hollow fiber membrane has a thickness of 30 μm.
The selectively permeable hollow fiber membrane according to claim 1, which is as described above.
み立て測定した、牛血漿でのβ2 ―マイクログロブリン
の総括物質移動係数が5.0×10-5cm/sec以上
である、特許請求の範囲第1項に記載の選択透過性中空
糸膜。4. A patent wherein the total permeability coefficient of β 2 -microglobulin in bovine plasma is 5.0 × 10 −5 cm / sec or more, as measured by assembling and measuring the permselective hollow fiber membrane as a dialyzer. The selectively permeable hollow fiber membrane according to claim 1.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28825596A JP3253867B2 (en) | 1996-10-30 | 1996-10-30 | Permselective hollow fiber membrane |
CA002202969A CA2202969C (en) | 1996-04-19 | 1997-04-17 | Selectively permeable hollow fiber membrane and process for producing same |
US08/837,475 US6013182A (en) | 1996-04-19 | 1997-04-18 | Selectively permeable hollow fiber membrane and process for producing same |
EP97302660A EP0801973A1 (en) | 1996-04-19 | 1997-04-18 | Selectively permeable hollow fiber membrane and process for producing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28825596A JP3253867B2 (en) | 1996-10-30 | 1996-10-30 | Permselective hollow fiber membrane |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10127763A true JPH10127763A (en) | 1998-05-19 |
JP3253867B2 JP3253867B2 (en) | 2002-02-04 |
Family
ID=17727838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP28825596A Expired - Lifetime JP3253867B2 (en) | 1996-04-19 | 1996-10-30 | Permselective hollow fiber membrane |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3253867B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002306937A (en) * | 2001-04-11 | 2002-10-22 | Daicel Chem Ind Ltd | Cellulose derivative hollow fiber membrane |
WO2007102528A1 (en) | 2006-03-09 | 2007-09-13 | Toyo Boseki Kabushiki Kaisha | Hollow fiber membrane with excellent performance stability and blood purifier and method for producing hollow fiber membrane |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5445195B2 (en) * | 2010-02-10 | 2014-03-19 | 東洋紡株式会社 | Blood purifier |
-
1996
- 1996-10-30 JP JP28825596A patent/JP3253867B2/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002306937A (en) * | 2001-04-11 | 2002-10-22 | Daicel Chem Ind Ltd | Cellulose derivative hollow fiber membrane |
WO2007102528A1 (en) | 2006-03-09 | 2007-09-13 | Toyo Boseki Kabushiki Kaisha | Hollow fiber membrane with excellent performance stability and blood purifier and method for producing hollow fiber membrane |
Also Published As
Publication number | Publication date |
---|---|
JP3253867B2 (en) | 2002-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0294737B1 (en) | Polysulfone hollow fiber membrane and process for making the same | |
EP0842694A1 (en) | Hollow yarn membrane used for blood purification and blood purifier | |
US6013182A (en) | Selectively permeable hollow fiber membrane and process for producing same | |
US5736046A (en) | High-flux hollow-fiber membrane with enhanced transport capability and process for making same | |
JP2000140589A (en) | Porous polysulfone film | |
JP3253861B2 (en) | Permselective hollow fiber membrane | |
JP3253867B2 (en) | Permselective hollow fiber membrane | |
JPH10263375A (en) | Selective permeable hollow fiber membrane | |
JP3295321B2 (en) | Permselective hollow fiber membrane | |
JP2703266B2 (en) | Polysulfone hollow fiber membrane and method for producing the same | |
JP3253885B2 (en) | Permselective hollow fiber membrane | |
JP3345260B2 (en) | Permselective hollow fiber membrane | |
JPH09308685A (en) | Hollow fiber membrane for blood purification and blood purifying device | |
JP3424810B2 (en) | High performance blood purification membrane | |
JP3236233B2 (en) | Method for producing selectively permeable hollow fiber membrane | |
JP3295314B2 (en) | Permselective hollow fiber membrane | |
JP3205268B2 (en) | Method for producing selectively permeable hollow fiber membrane | |
JP2000107577A (en) | Production of permselective hollow fiber membranes | |
JP4003982B2 (en) | Polysulfone-based selectively permeable separation membrane | |
JPH09308684A (en) | Selective separating membrane | |
JP3205267B2 (en) | Method for producing selectively permeable hollow fiber membrane | |
JP2000210544A (en) | Production of semipermeable membrane | |
JP2004216328A (en) | Permselective hollow fiber membrane and blood treatment instrument using the same | |
JP2812890B2 (en) | Blood purifier | |
JP3253875B2 (en) | Permselective hollow fiber membrane |